SEC Form 4 · accession 0001209191-18-004229
Foundation Medicine, Inc. · FMI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vincent A. Miller
Officer — Chief Medical Officer
Period of report
Jan 16, 2018
Accepted (ET)
Jan 18, 2018 · 4:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001488613
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 16, 2018 | S | 3,813 | $65.26 | D | 93,322 | D | |
| Common Stock | Jan 16, 2018 | M | 5,408 | $0.84 | A | 98,730 | D | |
| Common StockF1,F2 | Jan 16, 2018 | S | 5,408 | $65.26 | D | 93,322 | D | |
| Common Stock | Jan 17, 2018 | M | 5,534 | $0.84 | A | 98,856 | D | |
| Common StockF1,F3 | Jan 17, 2018 | S | 5,534 | $65.39 | D | 93,322 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $0.84 | Jan 16, 2018 | M | 5,408 | D | — | Jan 10, 2022 | Common Stock | 5,408 | 5,534 | D |
| Stock Option (right to buy)F4 | $0.84 | Jan 17, 2018 | M | 5,534 | D | — | Jan 10, 2022 | Common Stock | 5,534 | 0 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2017.
- F2The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.15 to $68.75, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
- F3The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.00 to $66.00, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
- F4The option was granted on January 10, 2012 and vested in equal quarterly installments beginning on December 31, 2012 until fully vested on April 8, 2016.